Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,916,131

« Back to Dashboard
Patent 8,916,131 protects VIZAMYL and is included in one NDA.

This patent has nineteen patent family members in eighteen countries.

Summary for Patent: 8,916,131

Title:Radiopharmaceutical composition
Abstract: The present invention relates to radiopharmaceuticals and in particular to a radiopharmaceutical composition comprising a compound of Formula (I): and polysorbate as an excipient. The radiopharmaceutical composition of the invention reduces problems encountered with prior art compositions comprising the same class of compounds. Also provided by the invention is a method for the preparation of the radiopharmaceutical composition of the invention as well as particular uses of the radiopharmaceutical composition. ##STR00001##
Inventor(s): Roed; Line (Oslo, NO), Peterson; Sarah Elizabeth (Amersham, GB)
Assignee: GE Healthcare Limited (Buckinghamshire, GB)
Application Number:12/673,602
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ge Healthcare
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYes8,916,131Sep 16, 2028Y
Ge Healthcare
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYes8,916,131Sep 16, 2028Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,916,131

PCT Information
PCT FiledAugust 28, 2008PCT Application Number:PCT/EP2008/061275
PCT Publication Date:March 05, 2009PCT Publication Number: WO2009/027452

International Patent Family for Patent: 8,916,131

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2475267<disabled in preview>
Russian Federation2010101935<disabled in preview>
Portugal2182988<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.